TY  - JOUR
AU  - Alonso, Rafael
AU  - Cedena, María-Teresa
AU  - Wong, Sandy
AU  - Shah, Nina
AU  - Ríos-Tamayo, Rafael
AU  - Moraleda, José M
AU  - López-Jiménez, Javier
AU  - García, Cristina
AU  - Bahri, Natasha
AU  - Valeri, Antonio
AU  - Sánchez, Ricardo
AU  - Collado-Yurrita, Luis
AU  - Martin, Thomas
AU  - Wolf, Jeffrey
AU  - Lahuerta, Juan-José
AU  - Martínez-López, Joaquín
PY  - 2020
DO  - 10.1182/bloodadvances.2020001508
UR  - http://hdl.handle.net/10668/15603
T2  - Blood advances
AB  - Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to improve progression-free survival (PFS) and, in several studies, overall survival. Nevertheless, the impact of...
LA  - en
KW  - Humans
KW  - Lenalidomide
KW  - Multiple Myeloma
KW  - Neoplasm, Residual
KW  - Retrospective Studies
KW  - Treatment Outcome
TI  - Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
TY  - research article
VL  - 4
ER  -